RT Journal Article
SR Electronic
T1 Sex differences in clinical findings among patients with coronavirus disease 2019 (COVID-19) and severe condition
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.27.20027524
DO 10.1101/2020.02.27.20027524
A1 Li, Jing
A1 Zhang, Yinghua
A1 Wang, Fang
A1 Liu, Bing
A1 Li, Hui
A1 Tang, Guodong
A1 Chang, Zhigang
A1 Liu, Aihua
A1 Fu, Chunyi
A1 Gao, Jing
A1 Li, Jing
YR 2020
UL http://medrxiv.org/content/early/2020/02/29/2020.02.27.20027524.abstract
AB Objective To compare the sex differences in the clinical findings among patients with severe coronavirus disease 2019 (COVID-19).Methods We retrospectively collected data of 47 patients diagnosed as severe type of COVID-19 from February 8 to 22, 2020, including demographics, illness history, physical examination, laboratory test, management, and compared differences between men and women.Results Of the 47 patients, 28 (59.6%) were men. The median age was 62 years, and 30 (63.8%) had comorbidities. The initial symptoms were mainly fever (34 [72.3%]), cough (36 [76.6%]), myalgia (5 [10.6%]) and fatigue (7 [14.9%]). Procalcitonin level was higher in men than in women (0.08 vs. 0.04ng/ml, p=0.002). N-terminal-pro brain natriuretic peptide increased in 16 (57.1%) men and 5 (26.3%) women (p=0.037). Five men (17.9%) had detected positive influenza A antibody, but no women. During 2-week admission, 5 (17.9%) men and 1 (5.3%) woman were reclassified into the critical type due to deterioration. Mortality was 3.6% in men and 0 in women respectively. Four (21.1%) women and one man (3.6%) recovered and discharged from hospital.Conclusion Sex differences may exist in COVID-19 patients of severe type. Men are likely to have more complicated clinical condition and worse in-hospital outcomes as compared to women.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Beijing Municipal Natural Science Foundation (No.7192078). The funder was not involved in the collection, analysis, or interpretation of data, or in the writing or submitting of this report.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additional data available.